📊 CAPR Key Takeaways
Is Capricor Therapeutics, Inc.. (CAPR) a Good Investment?
Capricor Therapeutics is a pre-revenue clinical-stage pharmaceutical company burning $29.3M annually with zero commercialized products, resulting in accelerating losses (EPS down 96.5% YoY). While the balance sheet is fortress-like with $105.4M in cash and zero debt, the 3.6-year cash runway and complete lack of revenue generation create substantial execution risk with uncertain path to profitability.
Capricor Therapeutics has very weak current operating fundamentals, with no reported revenue, large operating and net losses, and materially negative free cash flow, which indicates the business is still highly dependent on future clinical and regulatory execution rather than commercial performance. Offsetting that, the balance sheet is unusually strong for a development-stage biotech, with $287.85M in cash, no meaningful long-term debt, and high liquidity, giving the company meaningful financial flexibility and runway. Fundamentally, this looks like a high-risk clinical-stage story where balance-sheet strength supports survival, but profitability quality remains poor until revenue generation becomes durable.
Capricor Therapeutics, Inc.. Key Strengths (CAPR)
- Strong balance sheet: $278.7M stockholders equity with zero long-term debt
- Substantial cash reserves of $105.4M providing 3-4 year runway at current burn rate
- Excellent liquidity position: 8.42x current ratio demonstrating operational flexibility
- Conservative capital structure with no debt burden reducing financial stress
- Very strong liquidity with a 9.01x current and quick ratio
- Large cash balance of $287.85M relative to liabilities of $50.16M
- No meaningful long-term debt, reducing financial leverage risk
CAPR Stock Risks: Capricor Therapeutics, Inc.. Investment Risks
- Complete absence of revenue indicating pre-commercial stage with uncertain product timelines
- Operating losses accelerating: -$36.8M operating income with EPS deteriorating 96.5% YoY
- Significant cash burn of -$34.4M free cash flow annually consuming equity capital
- Pharma development risk: dependent entirely on clinical success, regulatory approval, and market acceptance with no proven products
- No revenue base, making growth quality and business durability unproven
- Heavy losses with operating income of -$108.14M and net income of -$105.04M
- Negative operating cash flow and free cash flow indicate ongoing cash burn
Key Metrics to Watch
- Revenue achievement and first commercial product launch timeline
- Operating cash burn trend and cash runway extension milestones
- Clinical trial progression and regulatory approval status for pipeline candidates
- Changes in stockholders equity depletion rate and path to profitability
- Quarterly cash burn relative to the $287.85M cash balance
- Transition from pre-revenue status to sustained product or collaboration revenue
Capricor Therapeutics, Inc.. (CAPR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.42x current ratio provides a solid financial cushion.
CAPR Profit Margin, ROE & Profitability Analysis
CAPR vs Healthcare Sector: How Capricor Therapeutics, Inc.. Compares
How Capricor Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Capricor Therapeutics, Inc.. Stock Overvalued? CAPR Valuation Analysis 2026
Based on fundamental analysis, Capricor Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Capricor Therapeutics, Inc.. Balance Sheet: CAPR Debt, Cash & Liquidity
CAPR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Capricor Therapeutics, Inc..'s revenue has grown significantly by 7,078% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.15 indicates the company is currently unprofitable.
CAPR Revenue Growth, EPS Growth & YoY Performance
CAPR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.3M | -$9.8M | $-0.38 |
| Q2 2025 | $4.0M | -$9.8M | $-0.35 |
| Q1 2025 | $4.9M | -$9.8M | $-0.31 |
| Q3 2024 | $2.3M | -$6.4M | $-0.25 |
| Q2 2024 | $3.9M | -$7.4M | $-0.29 |
| Q1 2024 | $3.0M | -$7.8M | $-0.31 |
| Q3 2023 | $1.6M | -$6.4M | $-0.25 |
| Q2 2023 | $3.9M | -$7.1M | $-0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Capricor Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
CAPR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Capricor Therapeutics, Inc.. (CIK: 0001133869)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CAPR
What is the AI rating for CAPR?
Capricor Therapeutics, Inc.. (CAPR) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CAPR's key strengths?
Claude: Strong balance sheet: $278.7M stockholders equity with zero long-term debt. Substantial cash reserves of $105.4M providing 3-4 year runway at current burn rate. ChatGPT: Very strong liquidity with a 9.01x current and quick ratio. Large cash balance of $287.85M relative to liabilities of $50.16M.
What are the risks of investing in CAPR?
Claude: Complete absence of revenue indicating pre-commercial stage with uncertain product timelines. Operating losses accelerating: -$36.8M operating income with EPS deteriorating 96.5% YoY. ChatGPT: No revenue base, making growth quality and business durability unproven. Heavy losses with operating income of -$108.14M and net income of -$105.04M.
What is CAPR's revenue and growth?
Capricor Therapeutics, Inc.. reported revenue of $0.0.
Does CAPR pay dividends?
Capricor Therapeutics, Inc.. does not currently pay dividends.
Where can I find CAPR SEC filings?
Official SEC filings for Capricor Therapeutics, Inc.. (CIK: 0001133869) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CAPR's EPS?
Capricor Therapeutics, Inc.. has a diluted EPS of $-0.59.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CAPR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Capricor Therapeutics, Inc.. has a C grade with 83% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CAPR stock overvalued or undervalued?
Valuation metrics for CAPR: ROE of -12.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CAPR's AI grade for 2026?
Our dual AI analysis gives Capricor Therapeutics, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CAPR's free cash flow?
Capricor Therapeutics, Inc..'s operating cash flow is $-29.3M, with capital expenditures of $5.1M.
How does CAPR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -12.2% (avg: 15%), current ratio 8.42 (avg: 2).